<DOC>
	<DOC>NCT00413699</DOC>
	<brief_summary>The purpose of this study is to determine the long-term effectiveness and safety of CP-690,550 for the treatment of rheumatoid arthritis. Subjects are eligible for this study only after participating in another "qualifying" study of CP-690,550 A sub-study will be conducted within the A3921024 study, this study will evaluate the immune response to pneumococcal and influenza vaccines in patients receiving CP-690,550</brief_summary>
	<brief_title>Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Subjects who have participated in a randomized "qualifying" study of CP690,550 for the treatment of rheumatoid arthritis Vaccine substudy visit Subjects actively participating in Study A3921024 must have completed at least 3 months of continuous 10 mg BID CP690,550 treatment in A3921024 as defined by &gt;80% compliance with prescribed dose consumption of CP690,550 over the previous 3 months. Serious medical conditions that would make treatment with CP690,550 potentially unsafe Vaccine substudy visit 1. Any documented influenza or pneumococcal infection within the last 3 months prior to randomization in this study 2. Received any vaccine within 1 month prior to randomization in this study 3. Received an influenza vaccine within 6 months or a pneumococcal vaccine within 5 years of randomization in this study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>long-term</keyword>
	<keyword>open-label</keyword>
	<keyword>safety</keyword>
</DOC>